创模生物科技(北京)有限公司

CN / En

NEWS

InnoModels: Introduction of iHuPBMC-NK Platform

  • Categories:Company news
  • Author:InnoModels
  • Origin:InnoModels
  • Time of issue:2024-02-29 13:55
  • Views:

(Summary description)​​​​​​​In today's rapid development of biotechnology, immunotherapy has become an important means of cancer treatment. In this field, the iHuPBMC-NK platform of InnoModels Biotechnology has attracted extensive attention from the industry due to its unique advantages and features. In this paper, we will introduce the features of iHuPBMC-NK platform in detail and look forward to its application prospect in the future immunotherapy field

InnoModels: Introduction of iHuPBMC-NK Platform

(Summary description)​​​​​​​In today's rapid development of biotechnology, immunotherapy has become an important means of cancer treatment. In this field, the iHuPBMC-NK platform of InnoModels Biotechnology has attracted extensive attention from the industry due to its unique advantages and features. In this paper, we will introduce the features of iHuPBMC-NK platform in detail and look forward to its application prospect in the future immunotherapy field

  • Categories:Company news
  • Author:InnoModels
  • Origin:InnoModels
  • Time of issue:2024-02-29 13:55
  • Views:
Information

In today's rapid development of biotechnology, immunotherapy has become an important means of cancer treatment. In this field, the iHuPBMC-NK platform of InnoModels Biotechnology has attracted extensive attention from the industry due to its unique advantages and features. In this paper, we will introduce the features of iHuPBMC-NK platform in detail and look forward to its application prospect in the future immunotherapy field.
I. Unique advantages of iHuPBMC-NK platform
1. Efficient NK cell proliferation: iHuPBMC-NK platform utilizes a unique culture technology that significantly improves the proliferation capacity of NK cells. Compared to traditional methods, the iHuPBMC-NK platform is able to obtain sufficient numbers of NK cells faster, shortening the treatment cycle and improving the timeliness of treatment.
2. Gene editing capability: With the help of CRISPR-Cas9 and other gene editing technologies, the iHuPBMC-NK platform is able to precisely genetically modify NK cells to give them stronger anti-tumor activity. This innovative technology will bring unprecedented breakthroughs in tumor immunotherapy.
3. Personalization: The iHuPBMC-NK platform can personalize the NK cell culture according to the patient's specific situation. This feature makes the treatment more targeted and can significantly improve the therapeutic effect and reduce side effects.
4. Safety guarantee: During the development of the iHuPBMC-NK platform, InnoModels Biotechnology strictly follows international safety standards to ensure the sterility of the entire culture and expansion process. Meanwhile, strict quality control of the culture medium is carried out to ensure the safety and effectiveness of NK cells.

 


Second, the application prospect of iHuPBMC-NK platform in the field of immunotherapy
1. Individualized immunotherapy: With the continuous development of precision medicine, individualized immunotherapy has become an important direction of cancer treatment. iHuPBMC-NK platform is expected to play a key role in this field by virtue of its personalized features, providing patients with more accurate and effective treatment plans.
2. Tumor immunotherapy: With the help of gene editing technology, the iHuPBMC-NK platform can enhance the anti-tumor activity of NK cells, further improving the efficacy of tumor immunotherapy. This will bring greater hope of survival for tumor patients.
3. Combination therapy strategy: In the future, the iHuPBMC-NK platform is expected to be combined with other immunotherapies or traditional therapies to form a combination therapy strategy. This multi-pronged treatment approach will be more effective against cancer and increase the cure rate.
4. Clinical trials and drug development: The iHuPBMC-NK platform can also be used to conduct clinical trials and drug development. Through this platform, researchers can evaluate the effectiveness and safety of new drugs and accelerate the drug development process.
5. Disease modeling research: In addition to direct application in patient treatment, the iHuPBMC-NK platform can also be used as a research tool to construct disease models and deeply investigate the molecular mechanisms and functions of immune cells. This will help scientists better understand the operation of the immune system and lay the foundation for future immunotherapy research.
To summarize, the iHuPBMC-NK platform of InnoModels Biotechnology has brought breakthroughs in the field of immunotherapy with its unique advantages and features. With the deepening of the research and the continuous improvement of the technology, we have reason to believe that the iHuPBMC-NK platform will play an increasingly important role in the field of immunotherapy in the future, and bring the hope of life to more patients.

Keyword:

In the vast field of oncology and tumor immunopharmacodynamics research, InnoModels Biotechnology (Beijing) Ltd. has become a leader in the industry with its outstanding innovation ability and profound scientific research background. This company, co-founded by scientists from Novo Nordisk China R&D Center, Sino-US Crown and Shanghai Jiao Tong University Institute of Immunology, has been committed to building a stable domestic platform of humanized mouse models of the immune system (HIS) and human tumor xenografts (PDX) since its establishment in 2020, to provide new drug discovery and development companies, translational medicine researchers, and tumor patients with new-generation laboratory animal models for new drug discovery companies, translational medicine researchers, and tumor patients
In recent years, many breakthroughs have been made in the field of biomedical research, among which iHuPBMC-T technology is undoubtedly a shining star. As an innovative platform built by InnoModels Biotechnology (Beijing) Co., Ltd, iHuPBMC-T, with its unique technological advantages, shows great potential in optimizing the reconstruction of human peripheral blood single nucleated cell (PBMC) model and immuno-oncology research.
Recently, InnoModels Biotechnology (Beijing) Co., Ltd. has made a major breakthrough in the field of pharmaceutical technology, and successfully obtained a patent entitled “Method and application for the detection of immune system rebuilding ability of PBMC”. This patent not only adds a new footnote to the R&D strength of InnoModels Biotechnology in the field of biomedicine, but also provides a strong technical support for the promotion of drug research and development and the establishment of humanized experimental animal models
With the rapid development of biotechnology, the in-depth study of the immune system has become the key to new drug discovery, disease diagnosis and treatment. InnoModels Bio-technology (Beijing) Co., Ltd. provides strong support for researchers with its profound scientific background and advanced technology platform. Among them, the ELISpot platform of InnoModels Biotechnology has made a name for itself in the field of immunology research with its high sensitivity and multi-functionality
InnoModels' ADCC platform plays a pivotal role in advancing cancer treatment, and its unique technological advantages and innovative concepts have brought about a far-reaching impact on the field of tumor immunotherapy. The following is a detailed introduction of how the platform promotes the advancement of cancer treatment
In the field of tumor immunotherapy, complement-dependent cytotoxicity (CDC), as an important therapeutic mechanism, is gradually showing its great potential and value. In order to explore this mechanism more deeply, with its profound accumulation in the field of oncology and tumor immunopharmacodynamics CRO services, InnoModels Biotechnology (Beijing) Co., Ltd. has launched the CDC in vitro immune-tumor cell co-culture killing experimental platform, which provides researchers with a powerful and precise tool to help innovate cancer treatment
Previous page
1
2
43
  • Tel 15010000264
  • E-mail limy@imodels.tech
  • Tel 13810723384
  • Top

InnoModels Biotechnology (Beijing) Co., Ltd.

TEL:15010000264        13810723384

Address:Building 14, Life Valley, Shuangying West Road, Changping District, Beijing

Chuangmo Biotechnology (Beijing) Co., Ltd. Beijing ICP 222*** 98-1 Website Construction: China Enterprise Power Beijing Second Branch Company

北京中因科技有限公司

创模生物科技(北京)有限公司